Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

Abstract

Bone metastasis (BoMet) is a common complication in various cancers. Approximately 20–30% of patients with cancer develop BoMet, which is most frequently associated with solid tumors, such as breast, prostate, and lung cancers. BoMet can lead to skeletal-related events such as fractures, bone pain, and hypercalcemia, negatively affecting the patient's quality of life and markedly shortening overall survival. The development of BoMet is a complex, multistep process driven by dynamic interactions between tumor cells and the bone microenvironment. The bone microenvironment provides a supportive niche for disseminated tumor cells, where intricate signaling networks and stromal interactions regulate the initiation, dormancy, reactivation, and progression of BoMet. Although current bone-targeted therapies can reduce the incidence of these complications, the clinical outcomes for patients with BoMet remain poor. Therefore, elucidating the molecular mechanisms governing these interactions is essential for identifying new therapeutic strategies. This review systematically explores the molecular drivers of BoMet progression, dynamic interactions within the metastatic niche, available preclinical models, established treatment modalities, and emerging therapeutic approaches. As fundamental research continues to advance toward clinical translation, the outlook for patients with BoMet is expected to improve significantly.

Keywords

bone metastasis / bone microenvironment / bone niche / bone-targeting therapy / cancer–bone crosstalk

References

[1] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[2] S. Gerstberger, Q. Jiang, and K. Ganesh, “Metastasis,” Cell 186, no. 8 (2023): 1564–1579.

[3] R. E. Coleman, “Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity,” Clinical Cancer Research 12, no. 20 Pt 2 (2006): 6243s–6249s.

[4] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[5] G. K. Guruvayurappan, T. Frankenbach-Desor, M. Laubach, et al., “Clinical Challenges in Prostate Cancer Management: Metastatic Bone-Tropism and the Role of Circulating Tumor Cells,” Cancer Letters 606 (2024): 217310.

[6] X. Zhang, “Interactions Between Cancer Cells and Bone Microenvironment Promote Bone Metastasis in Prostate Cancer,” Cancer Communications (London) 39, no. 1 (2019): 76.

[7] Y. Liang, H. Zhang, X. Song, and Q. Yang, “Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets,” Seminars in Cancer Biology 60 (2020): 14–27.

[8] M. Xue, L. Ma, P. Zhang, H. Yang, and Z. Wang, “New Insights Into Non-Small Cell Lung Cancer Bone Metastasis: Mechanisms and Therapies,” International Journal of Biological Sciences 20, no. 14 (2024): 5747–5763.

[9] R. Dai, M. Liu, X. Xiang, Z. Xi, and H. Xu, “Osteoblasts and Osteoclasts: An Important Switch of Tumour Cell Dormancy During Bone Metastasis,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 316.

[10] P. Clezardin, R. Coleman, M. Puppo, et al., “Bone Metastasis: Mechanisms, Therapies, and Biomarkers,” Physiological Reviews 101, no. 3 (2021): 797–855.

[11] J. N. Cheng, Z. Jin, and C. Su, “Bone Metastases Diminish Extraosseous Response to Checkpoint Blockade Immunotherapy Through Osteopontin-Producing Osteoclasts,” Cancer Cell 43, no. 6 (2025): 1093–1107.e9.

[12] I. J. Fidler, “The Pathogenesis of Cancer Metastasis: The ‘Seed and Soil’ hypothesis Revisited,” Nature Reviews Cancer 3, no. 6 (2003): 453–458.

[13] Y. Gao, I. Bado, H. Wang, W. Zhang, J. M. Rosen, and X. H. Zhang, “Metastasis Organotropism: Redefining the Congenial Soil,” Developmental Cell 49, no. 3 (2019): 375–391.

[14] S. Lamouille, J. Xu, and R. Derynck, “Molecular Mechanisms of Epithelial-Mesenchymal Transition,” Nature Reviews Molecular Cell Biology 15, no. 3 (2014): 178–196.

[15] J. Li, J. Wu, Y. Xie, and X. Yu, “Bone Marrow Adipocytes and Lung Cancer Bone Metastasis: Unraveling the Role of Adipokines in the Tumor Microenvironment,” Frontiers in Oncology 14 (2024): 1360471.

[16] F. C. Bidard, S. Michiels, S. Riethdorf, et al., “Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-Analysis,” JNCI: Journal of the National Cancer Institute 110, no. 6 (2018): 560–567.

[17] A. Kuske, T. M. Gorges, P. Tennstedt, et al., “Improved Detection of Circulating Tumor Cells in Non-Metastatic High-Risk Prostate Cancer Patients,” Scientific Reports 6 (2016): 39736.

[18] T. E. Sutherland, D. P. Dyer, and J. E. Allen, “The Extracellular Matrix and the Immune System: A Mutually Dependent Relationship,” Science 379, no. 6633 (2023): eabp8964.

[19] J. Xu, F. Gao, W. Liu, and X. Guan, “Cell-Cell Communication Characteristics in Breast Cancer Metastasis,” Cell Communication and Signaling 22, no. 1 (2024): 55.

[20] H. Peinado, H. Zhang, I. R. Matei, et al., “Pre-Metastatic Niches: Organ-Specific Homes for Metastases,” Nature Reviews Cancer 17, no. 5 (2017): 302–317.

[21] S. Braun, F. D. Vogl, B. Naume, et al., “A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer,” New England Journal of Medicine 353, no. 8 (2005): 793–802.

[22] L. C. Hofbauer, A. Bozec, M. Rauner, F. Jakob, S. Perner, and K. Pantel, “Novel Approaches to Target the Microenvironment of Bone Metastasis,” Nature Reviews Clinical Oncology 18, no. 8 (2021): 488–505.

[23] Z. Huang, J. Wen, Y. Wang, et al., “Bone Metastasis of Hepatocellular Carcinoma: Facts and Hopes From Clinical and Translational Perspectives,” Frontiers in Medicine 16, no. 4 (2022): 551–573.

[24] Q. Zhan, B. Liu, X. Situ, et al., “New Insights Into the Correlations Between Circulating Tumor Cells and Target Organ Metastasis,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 465.

[25] M. S. Sosa, P. Bragado, and J. A. Aguirre-Ghiso, “Mechanisms of Disseminated Cancer Cell Dormancy: An Awakening Field,” Nature Reviews Cancer 14, no. 9 (2014): 611–622.

[26] L. Y. Yu-Lee, G. Yu, and Y. C. Lee, “Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFbetaRIII-p38MAPK-pS249/T252RB Pathway,” Cancer Research 78, no. 11 (2018): 2911–2924.

[27] F. C. Cackowski, M. R. Eber, J. Rhee, et al., “Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy,” Journal of Cellular Biochemistry 118, no. 4 (2017): 891–902.

[28] W. Zhang, I. Bado, H. Wang, H. C. Lo, and X. H. Zhang, “Bone Metastasis: Find Your Niche and Fit in,” Trends in Cancer 5, no. 2 (2019): 95–110.

[29] J. Agudo, J. A. Aguirre-Ghiso, M. Bhatia, L. A. Chodosh, A. L. Correia, and C. A. Klein, “Targeting Cancer Cell Dormancy,” Nature Reviews Cancer 24, no. 2 (2024): 97–104.

[30] P. Baldominos, A. Barbera-Mourelle, O. Barreiro, et al., “Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche,” Cell 185, no. 10 (2022): 1694–1708.e19.

[31] W. Janni, F. D. Vogl, G. Wiedswang, et al., “Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse–a European Pooled Analysis,” Clinical Cancer Research 17, no. 9 (2011): 2967–2976.

[32] M. J. M. Magbanua, H. S. Rugo, L. Hauranieh, et al., “Genomic and Expression Profiling Reveal Molecular Heterogeneity of Disseminated Tumor Cells in Bone Marrow of Early Breast Cancer,” NPJ Breast Cancer 4 (2018): 31.

[33] T. Fehm, V. Muller, B. Aktas, et al., “HER2 status of Circulating Tumor Cells in Patients With Metastatic Breast Cancer: A Prospective, Multicenter Trial,” Breast Cancer Research and Treatment 124, no. 2 (2010): 403–412.

[34] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403.

[35] Y. Liu and X. Cao, “Characteristics and Significance of the Pre-Metastatic Niche,” Cancer Cell 30, no. 5 (2016): 668–681.

[36] W. Zhang, I. L. Bado, J. Hu, et al., “The Bone Microenvironment Invigorates Metastatic Seeds for Further Dissemination,” Cell 184, no. 9 (2021): 2471–2486.e20.

[37] Y. Huang, H. Wang, X. Yue, and X. Li, “Bone Serves as a Transfer Station for Secondary Dissemination of Breast Cancer,” Bone Research 11, no. 1 (2023): 21.

[38] R. Alam, A. Reva, D. G. Edwards, et al., “Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer,” Cancer Discovery 15, no. 4 (2025): 818–837.

[39] Y. Wu, H. Ai, Y. Xi, et al., “Osteoclast-Derived Apoptotic Bodies Inhibit Naive CD8(+) T Cell Activation via Siglec15, Promoting Breast Cancer Secondary Metastasis,” Cell Reports Medicine 4, no. 9 (2023): 101165.

[40] M. Wang, F. Xia, Y. Wei, and X. Wei, “Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis,” Bone Research 8, no. 1 (2020): 30.

[41] C. K. Chan, E. Y. Seo, J. Y. Chen, et al., “Identification and Specification of the Mouse Skeletal Stem Cell,” Cell 160, no. 1-2 (2015): 285–298.

[42] J. Zarrer, M. T. Haider, D. J. Smit, and H. Taipaleenmaki, “Pathological Crosstalk Between Metastatic Breast Cancer Cells and the Bone Microenvironment,” Biomolecules 10, no. 2 (2020): 337.

[43] A. P. Kusumbe, S. K. Ramasamy, and R. H. Adams, “Coupling of Angiogenesis and Osteogenesis by a Specific Vessel Subtype in Bone,” Nature 507, no. 7492 (2014): 323–328.

[44] T. M. Bodenstine, B. H. Beck, X. Cao, et al., “Pre-Osteoblastic MC3T3-E1 Cells Promote Breast Cancer Growth in Bone in a Murine Xenograft Model,” Chinese journal of cancer 30, no. 3 (2011): 189–196.

[45] S. Cambier, M. Gouwy, and P. Proost, “The Chemokines CXCL8 and CXCL12: Molecular and Functional Properties, Role in Disease and Efforts towards Pharmacological Intervention,” Cellular & Molecular Immunology 20, no. 3 (2023): 217–251.

[46] T. T. Price, M. L. Burness, A. Sivan, et al., “Dormant Breast Cancer Micrometastases Reside in Specific Bone Marrow Niches That Regulate Their Transit to and From Bone,” Science Translational Medicine 8, no. 340 (2016): 340ra73.

[47] P. Dutta, M. Sarkissyan, K. Paico, Y. Wu, and J. V. Vadgama, “MCP-1 Is Overexpressed in Triple-Negative Breast Cancers and Drives Cancer Invasiveness and Metastasis,” Breast Cancer Research and Treatment 170, no. 3 (2018): 477–486.

[48] S. Yang, Z. He, T. Wu, S. Wang, and H. Dai, “Glycobiology in Osteoclast Differentiation and Function,” Bone Research 11, no. 1 (2023): 55.

[49] Y. Tintut and L. L. Demer, “Effects of Bioactive Lipids and Lipoproteins on Bone,” Trends in Endocrinology and Metabolism 25, no. 2 (2014): 53–59.

[50] T. Negishi-Koga, M. Shinohara, N. Komatsu, et al., “Suppression of Bone Formation by Osteoclastic Expression of Semaphorin 4D,” Nature Medicine 17, no. 11 (2011): 1473–1480.

[51] K. B. S. Paiva and J. M. Granjeiro, “Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair,” Progress in Molecular Biology and Translational Science 148 (2017): 203–303.

[52] R. E. Coleman, P. I. Croucher, A. R. Padhani, et al., “Bone Metastases,” Nature Reviews Disease Primers 6, no. 1 (2020): 83.

[53] D. J. Papachristou, E. K. Basdra, and A. G. Papavassiliou, “Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions,” Medicinal Research Reviews 32, no. 3 (2012): 611–636.

[54] A. G. Robling and L. F. Bonewald, “The Osteocyte: New Insights,” Annual Review of Physiology 82 (2020): 485–506.

[55] J. Delgado-Calle and T. Bellido, “Osteocytes and Skeletal Pathophysiology,” Current Molecular Biology Reports 1, no. 4 (2015): 157–167.

[56] L. C. Hofbauer, T. D. Rachner, R. E. Coleman, and F. Jakob, “Endocrine Aspects of Bone Metastases,” The Lancet Diabetes & Endocrinology 2, no. 6 (2014): 500–512.

[57] J. Xiong, M. Onal, R. L. Jilka, R. S. Weinstein, S. C. Manolagas, and C. A. O'Brien, “Matrix-Embedded Cells Control Osteoclast Formation,” Nature Medicine 17, no. 10 (2011): 1235–1241.

[58] H. Zhou, W. Zhang, H. Li, et al., “Osteocyte Mitochondria Inhibit Tumor Development via STING-Dependent Antitumor Immunity,” Science Advances 10, no. 3 (2024): eadi4298.

[59] Y. Tabe, S. Yamamoto, K. Saitoh, et al., “Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells,” Cancer Research 77, no. 6 (2017): 1453–1464.

[60] Z. L. Sebo, E. Rendina-Ruedy, G. P. Ables, et al., “Bone Marrow Adiposity: Basic and Clinical Implications,” Endocrine Reviews 40, no. 5 (2019): 1187–1206.

[61] F. J. A. de Paula and C. J. Rosen, “Structure and Function of Bone Marrow Adipocytes,” Comprehensive Physiology 8, no. 1 (2017): 315–349.

[62] M. K. Herroon, E. Rajagurubandara, A. L. Hardaway, et al., “Bone Marrow Adipocytes Promote Tumor Growth in Bone via FABP4-Dependent Mechanisms,” Oncotarget 4, no. 11 (2013): 2108–2123.

[63] P. K. Fazeli, M. C. Horowitz, O. A. MacDougald, et al., “Marrow Fat and Bone–new Perspectives,” Journal of Clinical Endocrinology and Metabolism 98, no. 3 (2013): 935–945.

[64] C. Miggitsch, A. Meryk, E. Naismith, et al., “Human Bone Marrow Adipocytes Display Distinct Immune Regulatory Properties,” EBioMedicine 46 (2019): 387–398.

[65] J. B. Wu, L. Yin, C. Shi, et al., “MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions,” Cancer Cell 31, no. 3 (2017): 368–382.

[66] B. M. Abdallah, “Marrow Adipocytes Inhibit the Differentiation of Mesenchymal Stem Cells Into Osteoblasts via Suppressing BMP-Signaling,” Journal of Biomedical Science 24, no. 1 (2017): 11.

[67] H. Goto, A. Hozumi, M. Osaki, et al., “Primary human Bone Marrow Adipocytes Support TNF-Alpha-Induced Osteoclast Differentiation and Function Through RANKL Expression,” Cytokine 56, no. 3 (2011): 662–668.

[68] Z. S. Templeton, W. R. Lie, W. Wang, et al., “Breast Cancer Cell Colonization of the Human Bone Marrow Adipose Tissue Niche,” Neoplasia 17, no. 12 (2015): 849–861.

[69] C. F. Tsai, J. H. Chen, C. T. Wu, P. C. Chang, S. L. Wang, and W. L. Yeh, “Induction of Osteoclast-Like Cell Formation by Leptin-Induced Soluble Intercellular Adhesion Molecule Secreted From Cancer Cells,” Therapeutic Advances in Medical Oncology 11 (2019): 1758835919846806.

[70] M. D. Brown, C. Hart, E. Gazi, P. Gardner, N. Lockyer, and N. Clarke, “Influence of Omega-6 PUFA Arachidonic Acid and Bone Marrow Adipocytes on Metastatic Spread From Prostate Cancer,” British Journal of Cancer 102, no. 2 (2010): 403–413.

[71] Y. Zhang and Z. Zhang, “The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications,” Cellular & Molecular Immunology 17, no. 8 (2020): 807–821.

[72] S. Chen, J. Lei, H. Mou, et al., “Multiple Influence of Immune Cells in the Bone Metastatic Cancer Microenvironment on Tumors,” Frontiers in Immunology 15 (2024): 1335366.

[73] T. E. Kahkonen, J. M. Halleen, and J. Bernoulli, “Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis,” Cells 10, no. 6 (2021): 1529.

[74] E. Zhao, L. Wang, J. Dai, et al., “Regulatory T Cells in the Bone Marrow Microenvironment in Patients With Prostate Cancer,” Oncoimmunology 1, no. 2 (2012): 152–161.

[75] L. Xiang and D. M. Gilkes, “The Contribution of the Immune System in Bone Metastasis Pathogenesis,” International Journal of Molecular Sciences 20, no. 4 (2019): 999.

[76] W. Tan, W. Zhang, A. Strasner, et al., “Tumour-Infiltrating Regulatory T Cells Stimulate Mammary Cancer Metastasis Through RANKL-RANK Signalling,” Nature 470, no. 7335 (2011): 548–553.

[77] K. Titanji, “Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss,” Frontiers in Immunology 8 (2017): 1851.

[78] C. Bottino, V. Picant, E. Vivier, and R. Castriconi, “Natural Killer Cells and Engagers: Powerful Weapons Against Cancer,” Immunological Reviews 328, no. 1 (2024): 412–421.

[79] T. Okamoto, M. S. Yoneyama, S. Hatakeyama, et al., “Core2 O-Glycan-Expressing Prostate Cancer Cells Are Resistant to NK Cell Immunity,” Molecular Medicine Reports 7, no. 2 (2013): 359–364.

[80] T. Lazarov, S. Juarez-Carreno, N. Cox, and F. Geissmann, “Physiology and Diseases of Tissue-Resident Macrophages,” Nature 618, no. 7966 (2023): 698–707.

[81] M. Li, Y. Yang, L. Xiong, P. Jiang, J. Wang, and C. Li, “Metabolism, Metabolites, and Macrophages in Cancer,” Journal of Hematology & Oncology 16, no. 1 (2023): 80.

[82] B. Toledo, L. Zhu Chen, M. Paniagua-Sancho, J. A. Marchal, M. Peran, and E. Giovannetti, “Deciphering the Performance of Macrophages in Tumour Microenvironment: A Call for Precision Immunotherapy,” Journal of Hematology & Oncology 17, no. 1 (2024): 44.

[83] C. H. Lo and C. C. Lynch, “Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis,” Frontiers in Endocrinology (Lausanne) 9 (2018): 247.

[84] F. N. Soki, S. W. Cho, Y. W. Kim, et al., “Bone Marrow Macrophages Support Prostate Cancer Growth in Bone,” Oncotarget 6, no. 34 (2015): 35782–35796.

[85] X. Lu and Y. Kang, “Chemokine (C-C motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone,” Journal of Biological Chemistry 284, no. 42 (2009): 29087–29096.

[86] A. R. Sullivan and F. J. Pixley, “CSF-1R Signaling in Health and Disease: A Focus on the Mammary Gland,” Journal of Mammary Gland Biology and Neoplasia 19, no. 2 (2014): 149–159.

[87] Y. Wu, M. Yi, M. Niu, Q. Mei, and K. Wu, “Myeloid-Derived Suppressor Cells: An Emerging Target for Anticancer Immunotherapy,” Molecular Cancer 21, no. 1 (2022): 184.

[88] A. Sawant, J. Deshane, J. Jules, et al., “Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer,” Cancer Research 73, no. 2 (2013): 672–682.

[89] S. Danilin, A. R. Merkel, J. R. Johnson, R. W. Johnson, J. R. Edwards, and J. A. Sterling, “Myeloid-Derived Suppressor Cells Expand During Breast Cancer Progression and Promote Tumor-Induced Bone Destruction,” Oncoimmunology 1, no. 9 (2012): 1484–1494.

[90] K. L. Owen and B. S. Parker, “Beyond the Vicious Cycle: The Role of Innate Osteoimmunity, Automimicry and Tumor-Inherent Changes in Dictating Bone Metastasis,” Molecular Immunology 110 (2019): 57–68.

[91] L. D'Amico and I. Roato, “The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors,” Journal of Immunology Research 2015 (2015): 143526.

[92] L. Hato, A. Vizcay, I. Eguren, et al., “Dendritic Cells in Cancer Immunology and Immunotherapy,” Cancers (Basel) 16, no. 5 (2024): 981.

[93] L. L. Cavanagh, R. Bonasio, I. B. Mazo, et al., “Activation of Bone Marrow-Resident Memory T Cells by Circulating, Antigen-Bearing Dendritic Cells,” Nature Immunology 6, no. 10 (2005): 1029–1037.

[94] A. Sawant, J. A. Hensel, D. Chanda, et al., “Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells,” Journal of Immunology 189, no. 9 (2012): 4258–4265.

[95] M. R. Shurin, H. Naiditch, H. Zhong, and G. V. Shurin, “Regulatory Dendritic Cells: New Targets for Cancer Immunotherapy,” Cancer Biology & Therapy 11, no. 11 (2011): 988–992.

[96] C. L. Ihle, S. J. Wright-Hobart, and P. Owens, “Therapeutics Targeting the Metastatic Breast Cancer Bone Microenvironment,” Pharmacology & Therapeutics 239 (2022): 108280.

[97] N. Martinez-Sanchez, O. Sweeney, D. Sidarta-Oliveira, A. Caron, S. A. Stanley, and A. I. Domingos, “The Sympathetic Nervous System in the 21st Century: Neuroimmune Interactions in Metabolic Homeostasis and Obesity,” Neuron 110, no. 21 (2022): 3597–3626.

[98] F. Elefteriou, “Role of Sympathetic Nerves in the Establishment of Metastatic Breast Cancer Cells in Bone,” Journal of Bone Oncology 5, no. 3 (2016): 132–134.

[99] N. Ben-Ghedalia-Peled and R. Vago, “Wnt Signaling in the Development of Bone Metastasis,” Cells 11, no. 23 (2022): 3934.

[100] M. Holzem, M. Boutros, and T. W. Holstein, “The Origin and Evolution of Wnt Signalling,” Nature Reviews Genetics 25, no. 7 (2024): 500–512.

[101] K. S. Houschyar, C. Tapking, M. R. Borrelli, et al., “Wnt Pathway in Bone Repair and Regeneration—What Do We Know So Far,” Frontiers in Cell and Developmental Biology 6 (2018): 170.

[102] S. Nandana, M. Tripathi, P. Duan, et al., “Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis,” Cancer Research 77, no. 6 (2017): 1331–1344.

[103] G. Furesi, M. Rauner, and L. C. Hofbauer, “Emerging Players in Prostate Cancer-Bone Niche Communication,” Trends in Cancer 7, no. 2 (2021): 112–121.

[104] N. Jaschke, L. C. Hofbauer, A. Gobel, and T. D. Rachner, “Evolving Functions of Dickkopf-1 in Cancer and Immunity,” Cancer Letters 482 (2020): 1–7.

[105] X. Zhuang, H. Zhang, X. Li, et al., “Differential Effects on Lung and Bone Metastasis of Breast Cancer by Wnt Signalling Inhibitor DKK1,” Nature Cell Biology 19, no. 10 (2017): 1274–1285.

[106] D. V. F. Tauriello, E. Sancho, and E. Batlle, “Overcoming TGFbeta-Mediated Immune Evasion in Cancer,” Nature Reviews Cancer 22, no. 1 (2022): 25–44.

[107] H. Zheng, Y. Bae, S. Kasimir-Bauer, et al., “Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy,” Cancer Cell 32, no. 6 (2017): 731–747.e6.

[108] L. Zhang, J. Qu, Y. Qi, et al., “EZH2 engages TGFbeta Signaling to Promote Breast Cancer Bone Metastasis via Integrin beta1-FAK Activation,” Nature Communications 13, no. 1 (2022): 2543.

[109] Y. Wang, R. Lei, X. Zhuang, et al., “DLC1-Dependent Parathyroid Hormone-Like Hormone Inhibition Suppresses Breast Cancer Bone Metastasis,” Journal of Clinical Investigation 124, no. 4 (2014): 1646–1659.

[110] B. Zhou, W. Lin, and Y. Long, “Notch Signaling Pathway: Architecture, Disease, and Therapeutics,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 95.

[111] L. Liu, X. Chen, Y. Wang, et al., “Notch3 is Important for TGF-Beta-Induced Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Bone Metastasis by Regulating ZEB-1,” Cancer Gene Therapy 21, no. 9 (2014): 364–372.

[112] L. Yu, J. Wei, and P. Liu, “Attacking the PI3K/Akt/mTOR Signaling Pathway for Targeted Therapeutic Treatment in human Cancer,” Seminars in Cancer Biology 85 (2022): 69–94.

[113] C. Xue, G. Li, J. Lu, and L. Li, “Crosstalk Between circRNAs and the PI3K/AKT Signaling Pathway in Cancer Progression,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 400.

[114] Y. Tang, J. Pan, S. Huang, et al., “Downregulation of miR-133a-3p Promotes Prostate Cancer Bone Metastasis via Activating PI3K/AKT Signaling,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 160.

[115] J. Yuan, X. Dong, J. Yap, and J. Hu, “The MAPK and AMPK Signalings: Interplay and Implication in Targeted Cancer Therapy,” Journal of Hematology & Oncology 13, no. 1 (2020): 113.

[116] B. Murali, Q. Ren, X. Luo, et al., “Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss,” Cancer Research 78, no. 19 (2018): 5618–5630.

[117] E. S. Reis, D. C. Mastellos, D. Ricklin, A. Mantovani, and J. D. Lambris, “Complement in Cancer: Untangling an Intricate Relationship,” Nature Reviews Immunology 18, no. 1 (2018): 5–18.

[118] D. Ajona, C. Zandueta, L. Corrales, et al., “Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-Mediated Effects,” American Journal of Respiratory and Critical Care Medicine 197, no. 9 (2018): 1164–1176.

[119] J. Zhou and P. D. Ottewell, “The Role of IL-1B in Breast Cancer Bone Metastasis,” Journal of Bone Oncology 46 (2024): 100608.

[120] S. Wang, W. Wu, X. Lin, et al., “Predictive and Prognostic Biomarkers of Bone Metastasis in Breast Cancer: Current Status and Future Directions,” Cell & Bioscience 13, no. 1 (2023): 224.

[121] L. Monteran, N. Ershaid, Y. Scharff, et al., “Combining TIGIT Blockade With MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity,” Cancer Discovery 14, no. 7 (2024): 1252–1275.

[122] I. Holen, D. V. Lefley, S. E. Francis, et al., “IL-1 Drives Breast Cancer Growth and Bone Metastasis in Vivo,” Oncotarget 7, no. 46 (2016): 75571–75584.

[123] R. Y. Ma, H. Zhang, X. F. Li, et al., “Monocyte-Derived Macrophages Promote Breast Cancer Bone Metastasis Outgrowth,” Journal of Experimental Medicine 217, no. 11 (2020): e20191820.

[124] M. Liang, Q. Ma, N. Ding, et al., “IL-11 Is Essential in Promoting Osteolysis in Breast Cancer Bone Metastasis via RANKL-Independent Activation of Osteoclastogenesis,” Cell Death & Disease 10, no. 5 (2019): 353.

[125] Y. He, W. Luo, Y. Liu, et al., “IL-20RB Mediates Tumoral Response to Osteoclastic Niches and Promotes Bone Metastasis of Lung Cancer,” Journal of Clinical Investigation 132, no. 20 (2022): e157917.

[126] J. Y. Hung, D. Horn, K. Woodruff, et al., “Colony-Stimulating Factor 1 Potentiates Lung Cancer Bone Metastasis,” Laboratory Investigation 94, no. 4 (2014): 371–381.

[127] R. K. H. Yip, J. S. Rimes, B. D. Capaldo, et al., “Mammary Tumour Cells Remodel the Bone Marrow Vascular Microenvironment to Support Metastasis,” Nature Communications 12, no. 1 (2021): 6920.

[128] S. Raimondo, L. Saieva, E. Vicario, et al., “Multiple Myeloma-Derived Exosomes Are Enriched of Amphiregulin (AREG) and Activate the Epidermal Growth Factor Pathway in the Bone Microenvironment Leading to Osteoclastogenesis,” Journal of Hematology & Oncology 12, no. 1 (2019): 2.

[129] M. S. Bendre, A. G. Margulies, B. Walser, et al., “Tumor-Derived Interleukin-8 Stimulates Osteolysis Independent of the Receptor Activator of Nuclear Factor-Kappab Ligand Pathway,” Cancer Research 65, no. 23 (2005): 11001–11009.

[130] R. Romero-Moreno, K. J. Curtis, T. R. Coughlin, et al., “The CXCL5/CXCR2 Axis Is Sufficient to Promote Breast Cancer Colonization During Bone Metastasis,” Nature Communications 10, no. 1 (2019): 4404.

[131] S. Maji, A. K. Pradhan, A. Kumar, et al., “MDA-9/Syntenin in the Tumor and Microenvironment Defines Prostate Cancer Bone Metastasis,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 45 (2023): e2307094120.

[132] Z. Xin, L. Qin, Y. Tang, et al., “Immune Mediated Support of Metastasis: Implication for Bone Invasion,” Cancer Communications (London) 44, no. 9 (2024): 967–991.

[133] T. Liao, W. Chen, and J. Sun, “CXCR4 Accelerates Osteoclastogenesis Induced by Non-Small Cell Lung Carcinoma Cells through Self-Potentiation and VCAM1 Secretion,” Cellular Physiology and Biochemistry 50, no. 3 (2018): 1084–1099.

[134] P. Jiang, W. Gao, T. Ma, et al., “CD137 promotes Bone Metastasis of Breast Cancer by Enhancing the Migration and Osteoclast Differentiation of Monocytes/Macrophages,” Theranostics 9, no. 10 (2019): 2950–2966.

[135] W. Ouyang and A. O'Garra, “IL-10 Family Cytokines IL-10 and IL-22: From Basic Science to Clinical Translation,” Immunity 50, no. 4 (2019): 871–891.

[136] T. Assi, T. Moussa, C. Ngo, et al., “Therapeutic Advances in Tenosynovial Giant Cell Tumor: Targeting the CSF1/CSF1R Axis,” Cancer Treatment Reviews 134 (2025): 102904.

[137] M. C. Kruger, M. Coetzee, M. Haag, and H. Weiler, “Long-Chain Polyunsaturated Fatty Acids: Selected Mechanisms of Action on Bone,” Progress in Lipid Research 49, no. 4 (2010): 438–449.

[138] J. Y. Krzeszinski, A. G. Schwaid, W. Y. Cheng, et al., “Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis,” Endocrinology 158, no. 3 (2017): 477–489.

[139] H. Teng, Q. Hang, C. Zheng, et al., “In Vivo CRISPR Activation Screen Identifies Acyl-CoA-Binding Protein as a Driver of Bone Metastasis,” Science Translational Medicine 17, no. 799 (2025): eado7225.

[140] B. Li, J. Hao, J. Zeng, and E. R. Sauter, “SnapShot: FABP Functions,” Cell 182, no. 4 (2020): 1066–1066.e1.

[141] G. S. Hotamisligil and D. A. Bernlohr, “Metabolic Functions of FABPs–mechanisms and Therapeutic Implications,” Nature Reviews Endocrinology 11, no. 10 (2015): 592–605.

[142] K. Smolinska, A. Szopa, P. Dobrowolski, et al., “Targeting Fatty Acid-Binding Protein 4: A Therapeutic Intersection of Obesity and Cancer via Lipid Metabolism,” Progress in Lipid Research 100 (2025): 101353.

[143] O. Peyruchaud, B. Winding, I. Pecheur, C. M. Serre, P. Delmas, and P. Clezardin, “Early Detection of Bone Metastases in a Murine Model Using Fluorescent human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic Lesions,” Journal of Bone and Mineral Research 16, no. 11 (2001): 2027–2034.

[144] A. Boucharaba, C. M. Serre, S. Gres, et al., “Platelet-Derived Lysophosphatidic Acid Supports the Progression of Osteolytic Bone Metastases in Breast Cancer,” Journal of Clinical Investigation 114, no. 12 (2004): 1714–1725.

[145] O. Peyruchaud, R. Leblanc, and M. David, “Pleiotropic Activity of Lysophosphatidic Acid in Bone Metastasis,” Biochimica Et Biophysica Acta 1831, no. 1 (2013): 99–104.

[146] A. Grey, T. Banovic, D. Naot, et al., “Lysophosphatidic Acid Is an Osteoblast Mitogen whose Proliferative Actions Involve G(i) Proteins and Protein Kinase C, but Not P42/44 Mitogen-Activated Protein Kinases,” Endocrinology 142, no. 3 (2001): 1098–1106.

[147] A. Grey, Q. Chen, K. Callon, X. Xu, I. R. Reid, and J. Cornish, “The Phospholipids Sphingosine-1-Phosphate and Lysophosphatidic Acid Prevent Apoptosis in Osteoblastic Cells via a Signaling Pathway Involving G(i) Proteins and Phosphatidylinositol-3 Kinase,” Endocrinology 143, no. 12 (2002): 4755–4763.

[148] L. M. Masiello, J. S. Fotos, D. S. Galileo, and N. J. Karin, “Lysophosphatidic Acid Induces Chemotaxis in MC3T3-E1 Osteoblastic Cells,” Bone 39, no. 1 (2006): 72–82.

[149] Z. Pamuklar, J. S. Lee, H. Y. Cheng, et al., “Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid: Evidence for a Novel Inhibitory Pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology 28, no. 3 (2008): 555–561.

[150] I. Wortzel, S. Dror, C. M. Kenific, and D. Lyden, “Exosome-Mediated Metastasis: Communication From a Distance,” Developmental Cell 49, no. 3 (2019): 347–360.

[151] M. Borel, G. Lollo, D. Magne, R. Buchet, L. Brizuela, and S. Mebarek, “Prostate Cancer-Derived Exosomes Promote Osteoblast Differentiation and Activity Through Phospholipase D2,” Biochimica et Biophysica Acta: Molecular Basis of Disease 1866, no. 12 (2020): 165919.

[152] K. Glunde, Z. M. Bhujwalla, and S. M. Ronen, “Choline Metabolism in Malignant Transformation,” Nature Reviews Cancer 11, no. 12 (2011): 835–848.

[153] T. Harayama, M. Eto, H. Shindou, et al., “Lysophospholipid Acyltransferases Mediate Phosphatidylcholine Diversification to Achieve the Physical Properties Required in Vivo,” Cell Metabolism 20, no. 2 (2014): 295–305.

[154] X. Huang, B. R. Withers, and R. C. Dickson, “Sphingolipids and Lifespan Regulation,” Biochimica Et Biophysica Acta 1841, no. 5 (2014): 657–664.

[155] J. Ryu, H. J. Kim, E. J. Chang, H. Huang, Y. Banno, and H. H. Kim, “Sphingosine 1-Phosphate as a Regulator of Osteoclast Differentiation and Osteoclast-Osteoblast Coupling,” The EMBO Journal 25, no. 24 (2006): 5840–5851.

[156] M. Ishii, J. G. Egen, F. Klauschen, et al., “Sphingosine-1-Phosphate Mobilizes Osteoclast Precursors and Regulates Bone Homeostasis,” Nature 458, no. 7237 (2009): 524–528.

[157] M. Kono, Y. Mi, Y. Liu, et al., “The Sphingosine-1-Phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately During Embryonic Angiogenesis,” Journal of Biological Chemistry 279, no. 28 (2004): 29367–29373.

[158] T. Ishii, Y. Shimazu, I. Nishiyama, J. Kikuta, and M. Ishii, “The Role of Sphingosine 1-Phosphate in Migration of Osteoclast Precursors; an Application of Intravital Two-Photon Microscopy,” Molecules and Cells 31, no. 5 (2011): 399–403.

[159] M. Ishii, J. Kikuta, Y. Shimazu, M. Meier-Schellersheim, and R. N. Germain, “Chemorepulsion by Blood S1P Regulates Osteoclast Precursor Mobilization and Bone Remodeling in Vivo,” Journal of Experimental Medicine 207, no. 13 (2010): 2793–2798.

[160] T. Roelofsen, R. Akkers, W. Beumer, et al., “Sphingosine-1-Phosphate Acts as a Developmental Stage Specific Inhibitor of Platelet-Derived Growth Factor-Induced Chemotaxis of Osteoblasts,” Journal of Cellular Biochemistry 105, no. 4 (2008): 1128–1138.

[161] P. Quint, M. Ruan, L. Pederson, et al., “Sphingosine 1-Phosphate (S1P) Receptors 1 and 2 Coordinately Induce Mesenchymal Cell Migration Through S1P Activation of Complementary Kinase Pathways,” Journal of Biological Chemistry 288, no. 8 (2013): 5398–5406.

[162] A. Grey, X. Xu, B. Hill, et al., “Osteoblastic Cells Express Phospholipid Receptors and Phosphatases and Proliferate in Response to Sphingosine-1-Phosphate,” Calcified Tissue International 74, no. 6 (2004): 542–550.

[163] S. Spiegel and S. Milstien, “The Outs and the Ins of Sphingosine-1-Phosphate in Immunity,” Nature Reviews Immunology 11, no. 6 (2011): 403–415.

[164] D. Li, H. Lv, X. Hao, B. Hu, and Y. Song, “Prognostic Value of Serum Alkaline Phosphatase in the Survival of Prostate Cancer: Evidence From a Meta-Analysis,” Cancer Management and Research 10 (2018): 3125–3139.

[165] A. G. Hansen, S. A. Arnold, M. Jiang, et al., “ALCAM/CD166 Is a TGF-Beta-Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone,” Cancer Research 74, no. 5 (2014): 1404–1415.

[166] C. Mehra, J. H. Chung, Y. He, et al., “CdGAP Promotes Prostate Cancer Metastasis by Regulating Epithelial-to-Mesenchymal Transition, Cell Cycle Progression, and Apoptosis,” Communications Biology 4, no. 1 (2021): 1042.

[167] C. Meng, K. Lin, W. Shi, et al., “Histone Methyltransferase ASH1L Primes Metastases and Metabolic Reprogramming of Macrophages in the Bone Niche,” Nature Communications 16, no. 1 (2025): 4681.

[168] S. Huang, Q. Wa, J. Pan, et al., “Downregulation of miR-141-3p Promotes Bone Metastasis via Activating NF-KkappaB Signaling in Prostate Cancer,” Journal of Experimental & Clinical Cancer Research 36, no. 1 (2017): 173.

[169] A. M. Muscarella, S. Aguirre, X. Hao, S. M. Waldvogel, and X. H. Zhang, “Exploiting Bone Niches: Progression of Disseminated Tumor Cells to Metastasis,” Journal of Clinical Investigation 131, no. 6 (2021): e143764.

[170] W. Wang, X. Yang, J. Dai, Y. Lu, J. Zhang, and E. T. Keller, “Prostate Cancer Promotes a Vicious Cycle of Bone Metastasis Progression Through Inducing Osteocytes to Secrete GDF15 That Stimulates Prostate Cancer Growth and Invasion,” Oncogene 38, no. 23 (2019): 4540–4559.

[171] K. Hashimoto, H. Ochi, S. Sunamura, et al., “Cancer-Secreted Hsa-miR-940 Induces an Osteoblastic Phenotype in the Bone Metastatic Microenvironment via Targeting ARHGAP1 and FAM134A,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 9 (2018): 2204–2209.

[172] X. Ye, X. Huang, X. Fu, et al., “Myeloid-Like Tumor Hybrid Cells in Bone Marrow Promote Progression of Prostate Cancer Bone Metastasis,” Journal of Hematology & Oncology 16, no. 1 (2023): 46.

[173] L. Liao, “Inequality in Breast Cancer: Global Statistics From 2022 to 2050,” Breast (Edinburgh, Scotland) 79 (2025): 103851.

[174] R. M. Evans and D. J. Mangelsdorf, “Nuclear Receptors, RXR, and the Big Bang,” Cell 157, no. 1 (2014): 255–266.

[175] Q. Wu, P. Tian, D. He, et al., “SCUBE2 mediates Bone Metastasis of Luminal Breast Cancer by Modulating Immune-Suppressive Osteoblastic Niches,” Cell Research 33, no. 6 (2023): 464–478.

[176] D. F. Amanatullah, J. S. Tamaresis, P. Chu, et al., “Local Estrogen Axis in the human Bone Microenvironment Regulates Estrogen Receptor-Positive Breast Cancer Cells,” Breast Cancer Research 19, no. 1 (2017): 121.

[177] I. L. Bado, W. Zhang, J. Hu, et al., “The Bone Microenvironment Increases Phenotypic Plasticity of ER(+) Breast Cancer Cells,” Developmental Cell 56, no. 8 (2021): 1100–1117.e9.

[178] K. Wu, J. Feng, F. Lyu, et al., “Exosomal miR-19a and IBSP Cooperate to Induce Osteolytic Bone Metastasis of Estrogen Receptor-Positive Breast Cancer,” Nature Communications 12, no. 1 (2021): 5196.

[179] Y. Li, H. Zhang, Y. Zhao, et al., “A Mandatory Role of Nuclear PAK4-LIFR Axis in Breast-to-Bone Metastasis of ERalpha-Positive Breast Cancer Cells,” Oncogene 38, no. 6 (2019): 808–821.

[180] C. Feng, Z. Xu, X. Tang, H. Cao, G. Zhang, and J. Tan, “Estrogen-Related Receptor Alpha: A Significant Regulator and Promising Target in Bone Homeostasis and Bone Metastasis,” Molecules (Basel, Switzerland) 27, no. 13 (2022): 3976.

[181] E. Audet-Walsh and V. Giguere, “The Multiple Universes of Estrogen-Related Receptor Alpha and Gamma in Metabolic Control and Related Diseases,” Acta Pharmacologica Sinica 36, no. 1 (2015): 51–61.

[182] G. Vargas, M. Bouchet, L. Bouazza, et al., “ERRalpha Promotes Breast Cancer Cell Dissemination to Bone by Increasing RANK Expression in Primary Breast Tumors,” Oncogene 38, no. 7 (2019): 950–964.

[183] A. Fradet, H. Sorel, L. Bouazza, et al., “Dual Function of ERRalpha in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and Osteoprotegerin,” Cancer Research 71, no. 17 (2011): 5728–5738.

[184] M. Bouchet, A. Laine, C. Boyault, et al., “ERRalpha Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response,” Cancer Research 80, no. 13 (2020): 2914–2926.

[185] O. A. Sandiford, R. J. Donnelly, M. H. El-Far, et al., “Mesenchymal Stem Cell-Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells Into Dormancy at the Bone Marrow Perivascular Region,” Cancer Research 81, no. 6 (2021): 1567–1582.

[186] R. W. Johnson, E. C. Finger, M. M. Olcina, et al., “Induction of LIFR Confers a Dormancy Phenotype in Breast Cancer Cells Disseminated to the Bone Marrow,” Nature Cell Biology 18, no. 10 (2016): 1078–1089.

[187] X. Li, Y. Liang, C. Lian, et al., “CST6 protein and Peptides Inhibit Breast Cancer Bone Metastasis by Suppressing CTSB Activity and Osteoclastogenesis,” Theranostics 11, no. 20 (2021): 9821–9832.

[188] A. Sutherland, A. Forsyth, Y. Cong, et al., “The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation,” JNCI: Journal of the National Cancer Institute 108, no. 3 (2016): djv338.

[189] W. L. Cai, W. D. Huang, B. Li, et al., “microRNA-124 Inhibits Bone Metastasis of Breast Cancer by Repressing Interleukin-11,” Molecular cancer 17, no. 1 (2018): 9.

[190] K. Ke, O. J. Sul, M. Rajasekaran, and H. S. Choi, “MicroRNA-183 Increases Osteoclastogenesis by Repressing Heme Oxygenase-1,” Bone 81 (2015): 237–246.

[191] X. Yuan, N. Qian, S. Ling, et al., “Breast Cancer Exosomes Contribute to Pre-Metastatic Niche Formation and Promote Bone Metastasis of Tumor Cells,” Theranostics 11, no. 3 (2021): 1429–1445.

[192] S. Kir, H. Komaba, A. P. Garcia, et al., “PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer,” Cell Metabolism 23, no. 2 (2016): 315–323.

[193] K. Andrade, J. Fornetti, L. Zhao, et al., “RON Kinase: A Target for Treatment of Cancer-Induced Bone Destruction and Osteoporosis,” Science Translational Medicine 9, no. 374 (2017): eaai9338.

[194] Y. Han, H. Sarkar, Z. Xu, et al. Niche Macrophages Recycle Iron to Tumor Cells and Foster Erythroblast Mimicry to Promote Bone Metastasis and Anemia. bioRxiv. 2025.

[195] R. L. Satcher and X. H. Zhang, “Evolving Cancer-Niche Interactions and Therapeutic Targets During Bone Metastasis,” Nature Reviews Cancer 22, no. 2 (2022): 85–101.

[196] H. Wang, C. Yu, X. Gao, et al., “The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells,” Cancer Cell 27, no. 2 (2015): 193–210.

[197] M. L. Blake, M. Tometsko, R. Miller, J. C. Jones, and W. C. Dougall, “RANK Expression on Breast Cancer Cells Promotes Skeletal Metastasis,” Clinical & Experimental Metastasis 31, no. 2 (2014): 233–245.

[198] H. Wang, L. Tian, J. Liu, et al., “The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability,” Cancer Cell 34, no. 5 (2018): 823–839.e7.

[199] Y. Huang and L. Zhang, “Annual Progress of Clinical Research on Targeted Therapy for Nonsmall Cell Lung Cancer in 2022,” Cancer Innovation 2, no. 1 (2023): 25–35.

[200] M. Riihimaki, A. Hemminki, M. Fallah, et al., “Metastatic Sites and Survival in Lung Cancer,” Lung Cancer 86, no. 1 (2014): 78–84.

[201] T. Uekita, R. Yagi, T. Ichimura, and R. Sakai, “C9orf10/Ossa Regulates the Bone Metastasis of Established Lung Adenocarcinoma Cell Subline H322L-BO4 in a Mouse Model,” Genes to Cells 29, no. 4 (2024): 290–300.

[202] K. Valencia, C. Ormazabal, C. Zandueta, et al., “Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis,” Clinical Cancer Research 18, no. 4 (2012): 969–980.

[203] X. Y. Yang, J. J. Liao, and W. R. Xue, “FMNL1 Down-Regulation Suppresses Bone Metastasis Through Reducing TGF-Beta1 Expression in Non-Small Cell Lung Cancer (NSCLC),” Biomedicine & Pharmacotherapy 117 (2019): 109126.

[204] M. Wang, C. C. Chao, P. C. Chen, et al., “Thrombospondin Enhances RANKL-Dependent Osteoclastogenesis and Facilitates Lung Cancer Bone Metastasis,” Biochemical Pharmacology 166 (2019): 23–32.

[205] C. Zhang, J. Qin, L. Yang, et al., “Exosomal miR-328 Originated From Pulmonary Adenocarcinoma Cells Enhances Osteoclastogenesis via Downregulating Nrp-2 Expression,” Cell Death Discovery 8, no. 1 (2022): 405.

[206] Z. Xu, X. Liu, H. Wang, et al., “Lung Adenocarcinoma Cell-Derived Exosomal miR-21 Facilitates Osteoclastogenesis,” Gene 666 (2018): 116–122.

[207] A. Brouns, L. E. L. Hendriks, I. J. Robbesom-van den Berge, et al., “Association of RANKL and EGFR Gene Expression With Bone Metastases in Patients With Metastatic Non-Small Cell Lung Cancer,” Frontiers in Oncology 13 (2023): 1145001.

[208] Y. Takahara, K. Nakase, M. Nojiri, et al., “Relationship Between Clinical Features and Gene Mutations in Non-Small Cell Lung Cancer With Osteoblastic Bone Metastasis,” Cancer Treatment and Research Communications 28 (2021): 100440.

[209] W. G. Chen, J. Sun, W. W. Shen, et al., “Sema4D expression and Secretion Are Increased by HIF-1alpha and Inhibit Osteogenesis in Bone Metastases of Lung Cancer,” Clinical & Experimental Metastasis 36, no. 1 (2019): 39–56.

[210] H. L. Feng, P. Guo, J. Wang, et al., “[Association of the expression of leptin and leptin receptor With bone metastasis in pulmonary adenocarcinoma],” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 38, no. 11 (2016): 840–844.

[211] M. Olea-Flores, J. C. Juarez-Cruz, M. D. Zuniga-Eulogio, et al., “New Actors Driving the Epithelial-Mesenchymal Transition in Cancer: The Role of Leptin,” Biomolecules 10, no. 12 (2020): 1676.

[212] V. Longo, O. Brunetti, S. D'Oronzo, C. Ostuni, P. Gatti, and F. Silvestris, “Bone Metastases in Hepatocellular Carcinoma: An Emerging Issue,” Cancer and Metastasis Reviews 33, no. 1 (2014): 333–342.

[213] S. Zhang, Y. Xu, C. Xie, et al., “RNF219/alpha-Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications,” Advanced Science (Weinh) 8, no. 16 (2021): e2102956.

[214] L. Zhang, H. Niu, J. Ma, et al., “The Molecular Mechanism of LncRNA34a-Mediated Regulation of Bone Metastasis in Hepatocellular Carcinoma,” Molecular Cancer 18, no. 1 (2019): 120.

[215] Z. J. Ma, Y. Wang, H. F. Li, et al., “LncZEB1-AS1 regulates Hepatocellular Carcinoma Bone Metastasis via Regulation of the miR-302b-EGFR-PI3K-AKT Axis,” Journal of Cancer 11, no. 17 (2020): 5118–5128.

[216] Z. Huang, L. Chu, J. Liang, et al., “H19 Promotes HCC Bone Metastasis through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p,” Hepatology 74, no. 1 (2021): 214–232.

[217] S. Zhang, X. Liao, S. Chen, et al., “Large Oncosome-Loaded VAPA Promotes Bone-Tropic Metastasis of Hepatocellular Carcinoma via Formation of Osteoclastic Pre-Metastatic Niche,” Advanced Science (Weinh) 9, no. 31 (2022): e2201974.

[218] S. Han, L. Xue, Y. Wei, et al., “Bone Lesion-Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5-Targeting miR-3190-5p,” Advanced Science (Weinh) 10, no. 17 (2023): e2207080.

[219] J. Liu, S. Chen, W. Wang, et al., “Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Metastasis Through Chemokine-Activated Hedgehog and TGF-Beta Pathways,” Cancer Letters 379, no. 1 (2016): 49–59.

[220] C. Sun, A. Hu, S. Wang, et al., “ADAM17-Regulated CX3CL1 Expression Produced by Bone Marrow Endothelial Cells Promotes Spinal Metastasis From Hepatocellular Carcinoma,” International Journal of Oncology 57, no. 1 (2020): 249–263.

[221] H. Zheng, Z. J. Cheng, B. Liang, et al., “N(6)-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis,” International Journal of Biological Sciences 19, no. 4 (2023): 1009–1023.

[222] R. K. Tahara, T. M. Brewer, R. L. Theriault, and N. T. Ueno, “Bone Metastasis of Breast Cancer,” Advances in Experimental Medicine and Biology 1152 (2019): 105–129.

[223] W. J. Gradishar, M. S. Moran, J. Abraham, et al., “Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 20, no. 6 (2022): 691–722.

[224] M. Yang, C. Liu, and X. Yu, “Skeletal-Related Adverse Events During Bone Metastasis of Breast Cancer: Current Status,” Discovery Medicine 27, no. 149 (2019): 211–220.

[225] M. Beheshti, A. Rezaee, H. Geinitz, W. Loidl, C. Pirich, and W. Langsteger, “Evaluation of Prostate Cancer Bone Metastases With 18F-NaF and 18F-Fluorocholine PET/CT,” Journal of Nuclear Medicine 57, no. Suppl 3 (2016): 55S–60S.

[226] J. W. Lee, S. M. Lee, H. S. Lee, Y. H. Kim, and W. K. Bae, “Comparison of Diagnostic Ability Between (99m)Tc-MDP Bone Scan and (18)F-FDG PET/CT for Bone Metastasis in Patients With Small Cell Lung Cancer,” Annals of Nuclear Medicine 26, no. 8 (2012): 627–633.

[227] J. Brown, E. Rathbone, S. Hinsley, et al., “Associations between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results from the AZURE (BIG01/04) Trial,” JNCI: Journal of the National Cancer Institute 110, no. 8 (2018): 871–879.

[228] W. Dean-Colomb, K. R. Hess, E. Young, et al., “Elevated Serum P1NP Predicts Development of Bone Metastasis and Survival in Early-Stage Breast Cancer,” Breast Cancer Research and Treatment 137, no. 2 (2013): 631–636.

[229] X. Teng, L. Wei, L. Han, D. Min, and Y. Du, “Establishment of a Serological Molecular Model for the Early Diagnosis and Progression Monitoring of Bone Metastasis in Lung Cancer,” BMC Cancer 20, no. 1 (2020): 562.

[230] K. Valencia, M. Martin-Fernandez, C. Zandueta, et al., “miR-326 Associates With Biochemical Markers of Bone Turnover in Lung Cancer Bone Metastasis,” Bone 52, no. 1 (2013): 532–539.

[231] T. D. Rachner, S. Kasimir-Bauer, A. Gobel, et al., “Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer,” Clinical Cancer Research 25, no. 4 (2019): 1369–1378.

[232] E. K. Trapp, P. A. Fasching, T. Fehm, et al., “Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results From the Adjuvant SUCCESS a Trial,” Cancers (Basel) 14, no. 16 (2022): 3949.

[233] M. H. Elnagdy, O. Farouk, A. K. Seleem, and H. A. Nada, “TFF1 and TFF3 mRNAs Are Higher in Blood From Breast Cancer Patients With Metastatic Disease Than Those Without,” Journal of Oncology 2018 (2018): 4793498.

[234] N. Aceto, A. Bardia, B. S. Wittner, et al., “AR Expression in Breast Cancer CTCs Associates With Bone Metastases,” Molecular Cancer Research 16, no. 4 (2018): 720–727.

[235] K. H. Lee, K. J. Lee, T. Y. Kim, et al., “Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients,” Journal of Bone and Mineral Research 35, no. 10 (2020): 1838–1849.

[236] Y. Zhang, J. Li, Q. Yang, et al., “A Clinically Applicable AI System for Detection and Diagnosis of Bone Metastases Using CT Scans,” Nature Communications 16, no. 1 (2025): 4444.

[237] M. R. Smith, F. Saad, R. Coleman, et al., “Denosumab and Bone-Metastasis-Free Survival in Men With Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial,” Lancet 379, no. 9810 (2012): 39–46.

[238] C. Van Poznak, M. R. Somerfield, W. E. Barlow, et al., “Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update,” Journal of Clinical Oncology 35, no. 35 (2017): 3978–3986.

[239] C. Parker, S. Nilsson, D. Heinrich, et al., “Alpha Emitter Radium-,” New England Journal of Medicine 369, no. 3 (2013): 223.

[240] R. Chow, P. Hoskin, D. Hollenberg, et al., “Efficacy of Single Fraction Conventional Radiation Therapy for Painful Uncomplicated Bone Metastases: A Systematic Review and Meta-Analysis,” Annals of Palliative Medicine 6, no. 2 (2017): 125–142.

[241] A. Faris, J. Exposito, A. Martinez-Unica, et al., “The Efficacy of Three-Dimensional Conformal Radiation Therapy on Pain and Quality of Life in Patients With Painful Bone Metastases: A Prospective Study,” Croatian Medical Journal 61, no. 3 (2020): 215–222.

[242] B. J. J. Bindels, C. Mercier, R. Gal, et al., “Stereotactic Body and Conventional Radiotherapy for Painful Bone Metastases: A Systematic Review and Meta-Analysis,” JAMA Network Open 7, no. 2 (2024): e2355409.

[243] S. Zenda, Y. Nakagami, M. Toshima, et al., “Strontium-89 (Sr-89) Chloride in the Treatment of Various Cancer Patients With Multiple Bone Metastases,” International Journal of Clinical Oncology 19, no. 4 (2014): 739–743.

[244] A. I. Saito, T. Inoue, M. Kinoshita, T. Kosaka, and T. Mitsuhashi, “Strontium-89 Chloride Delivery for Painful Bone Metastases in Patients With a History of Prior Irradiation,” Irish Journal of Medical Science 192, no. 2 (2023): 569–574.

[245] C. Kratochwil, U. Haberkorn, and F. L. Giesel, “Radionuclide Therapy of Metastatic Prostate Cancer,” Seminars in Nuclear Medicine 49, no. 4 (2019): 313–325.

[246] M. Ashrafizadeh, B. Farhood, A. Eleojo Musa, S. Taeb, A. Rezaeyan, and M. Najafi, “Abscopal Effect in Radioimmunotherapy,” International Immunopharmacology 85 (2020): 106663.

[247] M. Miyagi, H. Katagiri, H. Murata, et al., “Osteosclerotic Change as a Therapeutic Response to gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone Metastasis,” BMC Pulmonary Medicine 22, no. 1 (2022): 491.

[248] D. L. Suzman, S. A. Boikos, and M. A. Carducci, “Bone-Targeting Agents in Prostate Cancer,” Cancer and Metastasis Reviews 33, no. 2-3 (2014): 619–628.

[249] M. Stapleton, K. Sawamoto, C. J. Almeciga-Diaz, et al., “Development of Bone Targeting Drugs,” International Journal of Molecular Sciences 18, no. 7 (2017): 1345.

[250] G. Makris, E. D. Tseligka, I. Pirmettis, M. S. Papadopoulos, I. S. Vizirianakis, and D. Papagiannopoulou, “Development and Pharmacological Evaluation of New Bone-Targeted (99m)Tc-Radiolabeled Bisphosphonates,” Molecular Pharmaceutics 13, no. 7 (2016): 2301–2317.

[251] M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon, “Emerging Anti-Cancer Molecular Mechanisms of Aminobisphosphonates,” Endocrine-Related Cancer 13, no. 1 (2006): 7–26.

[252] A. Panagiotakou, M. Yavropoulou, N. Nasiri-Ansari, et al., “Extra-Skeletal Effects of Bisphosphonates,” Metabolism 110 (2020): 154264.

[253] M. Gnant and P. Clezardin, “Direct and Indirect Anticancer Activity of Bisphosphonates: A Brief Review of Published Literature,” Cancer Treatment Reviews 38, no. 5 (2012): 407–415.

[254] T. D. Rachner, A. Gobel, M. Junker, et al., “Regulation of VEGF by Mevalonate Pathway Inhibition in Breast Cancer,” Journal of Bone Oncology 2, no. 3 (2013): 110–115.

[255] E. Giraudo, M. Inoue, and D. Hanahan, “An Amino-Bisphosphonate Targets MMP-9-Expressing Macrophages and Angiogenesis to Impair Cervical Carcinogenesis,” Journal of Clinical Investigation 114, no. 5 (2004): 623–633.

[256] G. Comito, C. Pons Segura, and M. L. Taddei, “Zoledronic Acid Impairs Stromal Reactivity by Inhibiting M2-Macrophages Polarization and Prostate Cancer-Associated Fibroblasts,” Oncotarget 8, no. 1 (2017): 118–132.

[257] G. Gruenbacher and M. Thurnher, “Mevalonate Metabolism in Immuno-Oncology,” Frontiers in Immunology 8 (2017): 1714.

[258] S. Meraviglia, M. Eberl, D. Vermijlen, et al., “In Vivo Manipulation of Vgamma9Vdelta2 T Cells With Zoledronate and Low-Dose Interleukin-2 for Immunotherapy of Advanced Breast Cancer Patients,” Clinical and Experimental Immunology 161, no. 2 (2010): 290–297.

[259] G. N. Hortobagyi, C. Van Poznak, W. G. Harker, et al., “Continued Treatment Effect of Zoledronic Acid Dosing every 12 vs 4 Weeks in Women with Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial,” JAMA Oncology 3, no. 7 (2017): 906–912.

[260] A. L. Himelstein, J. C. Foster, J. L. Khatcheressian, et al., “Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial,” Jama 317, no. 1 (2017): 48–58.

[261] A. F. Schott, W. E. Barlow, C. H. Van Poznak, et al., “Phase II Studies of Two Different Schedules of dasatinib in Bone Metastasis Predominant Metastatic Breast Cancer: SWOG S0622,” Breast Cancer Research and Treatment 159, no. 1 (2016): 87–95.

[262] M. R. Smith, S. Halabi, C. J. Ryan, et al., “Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (alliance),” Journal of Clinical Oncology 32, no. 11 (2014): 1143–1150.

[263] G. V. Scagliotti, P. Kosmidis, F. de Marinis, et al., “Zoledronic Acid in Patients With Stage IIIA/B NSCLC: Results of a Randomized, Phase III Study,” Annals of Oncology 23, no. 8 (2012): 2082–2087.

[264] R. J. Broom, V. Hinder, K. Sharples, et al., “Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial,” Clinical Genitourinary Cancer 13, no. 1 (2015): 50–58.

[265] Z. Wei, B. Pan, D. Jia, and Y. Yu, “Long-Term Safety and Efficacy of Bisphosphonate Therapy in Advanced Lung Cancer With Bone Metastasis,” Future Oncology 18, no. 18 (2022): 2257–2267.

[266] F. C. Liu, K. C. Luk, and Y. C. Chen, “Risk Comparison of Osteonecrosis of the Jaw in Osteoporotic Patients Treated With Bisphosphonates vs. denosumab: A Multi-Institutional Retrospective Cohort Study in Taiwan,” Osteoporosis International 34, no. 10 (2023): 1729–1737.

[267] A. T. Stopeck, A. Lipton, J. J. Body, et al., “Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study,” Journal of Clinical Oncology 28, no. 35 (2010): 5132–5139.

[268] D. Henry, S. Vadhan-Raj, V. Hirsh, et al., “Delaying Skeletal-Related Events in a Randomized Phase 3 Study of Denosumab versus Zoledronic Acid in Patients With Advanced Cancer: An Analysis of Data From Patients With Solid Tumors,” Supportive Care in Cancer 22, no. 3 (2014): 679–687.

[269] K. Fizazi, M. Carducci, M. Smith, et al., “Denosumab versus zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study,” Lancet 377, no. 9768 (2011): 813–822.

[270] J. Dupont, W. Appermans, M. Dejaeger, I. Wauters, M. R. Laurent, and E. Gielen, “Rebound-Associated Vertebral Fractures After Denosumab Discontinuation in a Lung Cancer Patient With Bone Metastases,” Bone Reports 16 (2022): 101582.

[271] F. Salvador, A. Llorente, and R. R. Gomis, “From Latency to Overt Bone Metastasis in Breast Cancer: Potential for Treatment and Prevention,” Journal of Pathology 249, no. 1 (2019): 6–18.

[272] S. Bartels, M. Christgen, A. Luft, et al., “Estrogen Receptor (ESR1) Mutation in Bone Metastases From Breast Cancer,” Modern Pathology 31, no. 1 (2018): 56–61.

[273] M. Cristofanilli, N. C. Turner, I. Bondarenko, et al., “Fulvestrant plus palbociclib versus fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial,” The Lancet Oncology 17, no. 4 (2016): 425–439.

[274] J. J. Body, S. Casimiro, and L. Costa, “Targeting Bone Metastases in Prostate Cancer: Improving Clinical Outcome,” Nature Reviews Urology 12, no. 6 (2015): 340–356.

[275] M. Nozawa, T. Inagaki, K. Nagao, et al., “Phase II Trial of Zoledronic Acid Combined With Androgen-Deprivation Therapy for Treatment-Naive Prostate Cancer With Bone Metastasis,” International Journal of Clinical Oncology 19, no. 4 (2014): 693–701.

[276] J. El-Amm, N. Patel, A. Freeman, and J. B. Aragon-Ching, “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide,” Clinical Medicine Insights: Oncology 7 (2013): 235–245.

[277] K. Fizazi, H. I. Scher, K. Miller, et al., “Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men With Castration-Resistant Prostate Cancer: Results From the Randomised, Phase 3 AFFIRM Trial,” The Lancet Oncology 15, no. 10 (2014): 1147–1156.

[278] E. S. Antonarakis, C. Lu, H. Wang, et al., “AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer,” New England Journal of Medicine 371, no. 11 (2014): 1028–1038.

[279] S. Su, J. Cao, X. Meng, et al., “Enzalutamide-Induced and PTH1R-Mediated TGFBR2 Degradation in Osteoblasts Confers Resistance in Prostate Cancer Bone Metastases,” Cancer Letters 525 (2022): 170–178.

[280] K. Fizazi, S. Foulon, J. Carles, et al., “Abiraterone plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-Label, Randomised, Phase 3 Study With a 2×2 Factorial Design,” Lancet 399, no. 10336 (2022): 1695–1707.

[281] N. Bock, T. Kryza, A. Shokoohmand, et al., “In Vitro Engineering of a Bone Metastases Model Allows for Study of the Effects of Antiandrogen Therapies in Advanced Prostate Cancer,” Science Advances 7, no. 27 (2021): eabg2564.

[282] C. J. Logothetis, E. Basch, A. Molina, et al., “Effect of Abiraterone Acetate and Prednisone Compared With Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data From the COU-AA-301 Randomised Trial,” The Lancet Oncology 13, no. 12 (2012): 1210–1217.

[283] Z. Li, M. Alyamani, J. Li, et al., “Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy,” Nature 533, no. 7604 (2016): 547–551.

[284] C. L. Vale, S. Burdett, L. H. M. Rydzewska, et al., “Addition of Docetaxel or Bisphosphonates to Standard of Care in Men With Localised or Metastatic, Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analyses of Aggregate Data,” The Lancet Oncology 17, no. 2 (2016): 243–256.

[285] C. Parker, A. Heidenreich, S. Nilsson, and N. Shore, “Current Approaches to Incorporation of Radium-223 in Clinical Practice,” Prostate Cancer and Prostatic Diseases 21, no. 1 (2018): 37–47.

[286] A Randomized Trial to Assess Patient Quality of Life and Function after Alternative Surgeries for Pathologic Fractures of the Femur. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT02164019.

[287] 1–2 PUNCH: Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT05115331.

[288] A. E. Mascia, E. C. Daugherty, Y. Zhang, et al., “Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial,” JAMA Oncology 9, no. 1 (2023): 62–69.

[289] FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT05524064.

[290] N. J. Spindler, M. V. O. Felter, O. Hansen, et al., “Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial,” International Journal of Radiation and Oncology in Biology and Physics (2025).

[291] A Pilot Study to Assess the Safety and Efficacy of Preoperative Stereotactic Body Radiotherapy for the Treatment of Metastatic Disease in Bone Requiring Surgical Stabilization. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT05038124.

[292] A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) with or without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT03795207.

[293] S. Thureau, V. Marchesi, M. H. Vieillard, et al., “Efficacy of Extracranial Stereotactic Body Radiation Therapy (SBRT) Added to Standard Treatment in Patients With Solid Tumors (breast, prostate and non-Small cell lung cancer) With up to 3 Bone-Only Metastases: Study Protocol for a Randomised Phase III Trial (STEREO-OS),” BMC Cancer 21, no. 1 (2021): 117.

[294] Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel plus Prednisone in Symptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer (mCRPC). National Library of Medicine (US), https://clinicaltrials.gov/study/NCT03230734.

[295] A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE). National Library of Medicine (US), https://clinicaltrials.gov/study/NCT03317392.

[296] E. F. Gillespie, J. C. Yang, N. J. Mathis, et al., “Prophylactic Radiation Therapy versus Standard of Care for Patients with High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial,” Journal of Clinical Oncology 42, no. 1 (2024): 38–46.

[297] Evaluation of Medical Practice in the Management of Bone Metastases after Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT02839291.

[298] Feasibility Study of Zetamet™ Bone Graft in the Repair of Bone Defects from Metastatic Breast Cancer in the Spinal Vertebral Body: A Phase 2A, Multicenter, Open-Labeled, Single-Arm Study. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT05280067.

[299] A. Adams, T. Jakob, A. Huth, et al., “Bone-Modifying Agents for Reducing Bone Loss in Women With Early and Locally Advanced Breast Cancer: A Network Meta-Analysis,” Cochrane Database of Systematic Reviews (Online) 7, no. 7 (2024): CD013451.

[300] A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain. National Library of Medicine (US), https://clinicaltrials.gov/study/NCT01833806.

[301] M. Fallon, M. Sopata, E. Dragon, et al., “A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects with Cancer Pain due to Bone Metastasis,” The Oncologist 28, no. 12 (2023): e1268–e1278.

[302] F. Foerster, D. Bamberger, J. Schupp, et al., “Dextran-Based Therapeutic Nanoparticles for Hepatic Drug Delivery,” Nanomedicine (London) 11, no. 20 (2016): 2663–2677.

[303] W. L. Ye, Y. P. Zhao, Y. Cheng, et al., “Bone Metastasis Target Redox-Responsive Micell for the Treatment of Lung Cancer Bone Metastasis and Anti-Bone Resorption,” Artificial Cells, Nanomedicine, and Biotechnology 46, no. sup1 (2018): 380–391.

[304] Z. Tian, L. Wu, C. Yu, et al., “Harnessing the Power of Antibodies to Fight Bone Metastasis,” Science Advances 7, no. 26 (2021): eabf2051.

[305] G. Zhong, Y. Miao, J. Zhou, et al., “Near-Infrared Light-Induced Photothermal and Immunotherapy System for Lung Cancer Bone Metastasis Treatment With Simultaneous Bone Repair,” Bioactive Materials 52 (2025): 182–199.

[306] M. Shu, J. Wang, Z. Xu, et al., “Targeting Nanoplatform Synergistic Glutathione Depletion-Enhanced Chemodynamic, Microwave Dynamic, and Selective-Microwave Thermal to Treat Lung Cancer Bone Metastasis,” Bioactive Materials 39 (2024): 544–561.

[307] H. Shimano and R. Sato, “SREBP-Regulated Lipid Metabolism: Convergent Physiology—divergent Pathophysiology,” Nature Reviews Endocrinology 13, no. 12 (2017): 710–730.

[308] J. Chen, Z. Wu, W. Ding, et al., “SREBP1 siRNA Enhance the Docetaxel Effect Based on a Bone-Cancer Dual-Targeting Biomimetic Nanosystem Against Bone Metastatic Castration-Resistant Prostate Cancer,” Theranostics 10, no. 4 (2020): 1619–1632.

[309] S. Peng, X. Chen, C. Huang, et al., “UBE2S as a Novel Ubiquitinated Regulator of p16 and Beta-Catenin to Promote Bone Metastasis of Prostate Cancer,” International Journal of Biological Sciences 18, no. 8 (2022): 3528–3543.

[310] L. Sun, Y. Zhang, G. Chen, et al., “Targeting SOST Using a Small-Molecule Compound Retards Breast Cancer Bone Metastasis,” Molecular Cancer 21, no. 1 (2022): 228.

[311] Y. Wang, Z. Xu, K. L. Wu, et al., “Siglec-15/Sialic Acid Axis as a central Glyco-Immune Checkpoint in Breast Cancer Bone Metastasis,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 5 (2024): e2312929121.

[312] G. Hang, X. Gu, Y. Gu, P. Gan, C. Hua, and A. Chen, “Dihydroartemisinin Inhibits Lung Cancer Bone Metastasis by Modulating Macrophage Polarization,” European Journal of Medical Research 30, no. 1 (2025): 247.

[313] M. Islam, B. M. Arlian, F. Pfrengle, S. Duan, S. A. Smith, and J. C. Paulson, “Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-Receptor Antibodies,” Journal of the American Chemical Society 144, no. 21 (2022): 9302–9311.

[314] R. Nazmabadi, M. Pooladi, J. Amri, Y. Abbasi, H. Karami, and M. Darvish, “Dihydroartemisinin Enhances the Therapeutic Efficacy of BH3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells via Inhibition of Mcl-1,” Asian Pacific Journal of Cancer Prevention 25, no. 1 (2024): 325–332.

[315] E. C. Gonzalez Diaz, S. Sinha, R. S. Avedian, and F. Yang, “Tissue-Engineered 3D Models for Elucidating Primary and Metastatic Bone Cancer Progression,” Acta Biomaterialia 99 (2019): 18–32.

[316] M. Khanmohammadi, M. Volpi, E. Walejewska, A. Olszewska, and W. Swieszkowski, “Printing of 3D Biomimetic Structures for the Study of Bone Metastasis: A Review,” Acta Biomaterialia 178 (2024): 24–40.

[317] L. S. Costard, R. R. Hosn, H. Ramanayake, F. J. O'Brien, and C. M. Curtin, “Influences of the 3D Microenvironment on Cancer Cell Behaviour and Treatment Responsiveness: A Recent Update on Lung, Breast and Prostate Cancer Models,” Acta Biomaterialia 132 (2021): 360–378.

[318] A. Shokoohmand, J. Ren, J. Baldwin, et al., “Microenvironment Engineering of Osteoblastic Bone Metastases Reveals Osteomimicry of Patient-Derived Prostate Cancer Xenografts,” Biomaterials 220 (2019): 119402.

[319] F. Nutter, I. Holen, H. K. Brown, et al., “Different Molecular Profiles Are Associated With Breast Cancer Cell Homing Compared With Colonisation of Bone: Evidence Using a Novel Bone-Seeking Cell Line,” Endocrine-Related Cancer 21, no. 2 (2014): 327–341.

[320] Y. Han, J. Nakayama, Y. Hayashi, et al., “Establishment and Characterization of Highly Osteolytic Luminal Breast Cancer Cell Lines by Intracaudal Arterial Injection,” Genes to Cells 25, no. 2 (2020): 111–123.

[321] C. Yu, H. Wang, A. Muscarella, et al., “Intra-Iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis,” Journal of Visualized Experiments: JoVE no. 115 (2016): 53982.

[322] D. Lefley, F. Howard, F. Arshad, et al., “Development of Clinically Relevant in Vivo Metastasis Models Using human Bone Discs and Breast Cancer Patient-Derived Xenografts,” Breast Cancer Research 21, no. 1 (2019): 130.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.